[1]
Tiller JW. The new and newer antianxiety agents. The Medical journal of Australia. 1989 Dec 4-18:151(11-12):697-701
[PubMed PMID: 2574409]
[2]
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in psychiatry. 2020:11():595584. doi: 10.3389/fpsyt.2020.595584. Epub 2020 Dec 23
[PubMed PMID: 33424664]
[3]
Howland RH. Buspirone: Back to the Future. Journal of psychosocial nursing and mental health services. 2015 Nov:53(11):21-4. doi: 10.3928/02793695-20151022-01. Epub
[PubMed PMID: 26535760]
[4]
Fava M,Targum SD,Nierenberg AA,Bleicher LS,Carter TA,Wedel PC,Hen R,Gage FH,Barlow C, An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. Journal of psychiatric research. 2012 Dec
[PubMed PMID: 22998742]
[5]
Rafeyan R, Papakostas GI, Jackson WC, Trivedi MH. Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies. The Journal of clinical psychiatry. 2020 May 12:81(3):. pii: OT19037BR3. doi: 10.4088/JCP.OT19037BR3. Epub 2020 May 12
[PubMed PMID: 32412697]
[6]
Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, dos Santos Souza JJ. Azapirones for generalized anxiety disorder. The Cochrane database of systematic reviews. 2006 Jul 19:2006(3):CD006115
[PubMed PMID: 16856115]
Level 1 (high-level) evidence
[7]
Giannoni A, Borrelli C, Mirizzi G, Richerson GB, Emdin M, Passino C. Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial. European journal of heart failure. 2021 Feb:23(2):312-320. doi: 10.1002/ejhf.1854. Epub 2020 May 22
[PubMed PMID: 32441857]
Level 1 (high-level) evidence
[8]
Tack J,Camilleri M, New developments in the treatment of gastroparesis and functional dyspepsia. Current opinion in pharmacology. 2018 Dec;
[PubMed PMID: 30245474]
Level 3 (low-level) evidence
[9]
Loane C, Politis M. Buspirone: what is it all about? Brain research. 2012 Jun 21:1461():111-8. doi: 10.1016/j.brainres.2012.04.032. Epub 2012 Apr 24
[PubMed PMID: 22608068]
[10]
Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. The American journal of medicine. 1986 Mar 31:80(3B):41-51
[PubMed PMID: 3515929]
[11]
Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clinical pharmacokinetics. 1999 Apr:36(4):277-87
[PubMed PMID: 10320950]
[12]
Strawn JR,Mills JA,Cornwall GJ,Mossman SA,Varney ST,Keeshin BR,Croarkin PE, Buspirone in Children and Adolescents with Anxiety: A Review and Bayesian Analysis of Abandoned Randomized Controlled Trials. Journal of child and adolescent psychopharmacology. 2018 Feb
[PubMed PMID: 28846022]
Level 1 (high-level) evidence
[13]
Hohmann N, Haefeli WE, Mikus G. CYP3A activity: towards dose adaptation to the individual. Expert opinion on drug metabolism & toxicology. 2016 May:12(5):479-97. doi: 10.1517/17425255.2016.1163337. Epub 2016 Mar 26
[PubMed PMID: 26950050]
Level 3 (low-level) evidence
[14]
Namazy J, Chambers C, Sahin L, Johnson T, Dinatale M, Lappin B, Schatz M. Clinicians' Perspective of the New Pregnancy and Lactation Labeling Rule (PLLR): Results from an AAAAI/FDA Survey. The journal of allergy and clinical immunology. In practice. 2020 Jun:8(6):1947-1952. doi: 10.1016/j.jaip.2020.01.056. Epub 2020 Feb 19
[PubMed PMID: 32084595]
Level 3 (low-level) evidence
[16]
O'Hanlon JF, Review of buspirone's effects on human performance and related variables. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 1991 Dec;
[PubMed PMID: 1822316]
[18]
Landén M, Eriksson E, Agren H, Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. Journal of clinical psychopharmacology. 1999 Jun:19(3):268-71
[PubMed PMID: 10350034]
[19]
Rissardo JP, Caprara ALF. Buspirone-associated Movement Disorder: A Literature Review. Prague medical report. 2020:121(1):5-24. doi: 10.14712/23362936.2020.1. Epub
[PubMed PMID: 32191616]
[20]
Moses TEH, Javanbakht A. New-Onset Sleepwalking in a Patient Treated With Buspirone. Journal of clinical psychopharmacology. 2022 Jan-Feb 01:42(1):96-98. doi: 10.1097/JCP.0000000000001476. Epub
[PubMed PMID: 34928565]
[21]
Stock EM, Zeber JE, McNeal CJ, Banchs JE, Copeland LA. Psychotropic Pharmacotherapy Associated With QT Prolongation Among Veterans With Posttraumatic Stress Disorder. The Annals of pharmacotherapy. 2018 Sep:52(9):838-848. doi: 10.1177/1060028018769425. Epub 2018 Apr 11
[PubMed PMID: 29642718]
[22]
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM : monthly journal of the Association of Physicians. 2003 Sep:96(9):635-42
[PubMed PMID: 12925718]
[23]
Morrison EK,Rowe AS, Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia. Journal of clinical pharmacy and therapeutics. 2012 Oct;
[PubMed PMID: 22452676]
[24]
Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. Clinical pharmacology and therapeutics. 1998 Dec:64(6):655-60
[PubMed PMID: 9871430]
[25]
Rush CR, Griffiths RR. Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Experimental and clinical psychopharmacology. 1997 Feb:5(1):28-38
[PubMed PMID: 9234037]
[26]
Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, Herzberg PY. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Medical care. 2008 Mar:46(3):266-74. doi: 10.1097/MLR.0b013e318160d093. Epub
[PubMed PMID: 18388841]
Level 1 (high-level) evidence
[27]
Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occupational medicine (Oxford, England). 2015 Oct:65(7):601. doi: 10.1093/occmed/kqv054. Epub
[PubMed PMID: 26370845]
[28]
Vaida AJ. The Institute for Safe Medication Practices and Poison Control Centers: Collaborating to Prevent Medication Errors and Unintentional Poisonings. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2015 Jun:11(2):262-4. doi: 10.1007/s13181-015-0475-y. Epub
[PubMed PMID: 25840933]
[29]
Salimi A, Razian M, Pourahmad J. Analysis of Toxicity Effects of Buspirone, Cetirizine and Olanzapine on Human Blood Lymphocytes: in Vitro Model. Current clinical pharmacology. 2018:13(2):120-127. doi: 10.2174/1574884713666180516112920. Epub
[PubMed PMID: 29766823]
[30]
Alam N, Najam R, Naeem S. Attenuation of methylphenidate-induced sensitization by co-administration of buspirone. Pakistan journal of pharmaceutical sciences. 2016 Mar:29(2):585-90
[PubMed PMID: 27087081]
[31]
Catalano G, Catalano MC, Hanley PF. Seizures associated with buspirone overdose: case report and literature review. Clinical neuropharmacology. 1998 Nov-Dec:21(6):347-50
[PubMed PMID: 9844791]
Level 3 (low-level) evidence
[32]
Griffith JD, Jasinski DR, Casten GP, McKinney GR. Investigation of the abuse liability of buspirone in alcohol-dependent patients. The American journal of medicine. 1986 Mar 31:80(3B):30-5
[PubMed PMID: 3963032]
[33]
Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert opinion on pharmacotherapy. 2018 Jul:19(10):1057-1070. doi: 10.1080/14656566.2018.1491966. Epub
[PubMed PMID: 30056792]
Level 3 (low-level) evidence
[34]
Muntingh AD, van der Feltz-Cornelis CM, van Marwijk HW, Spinhoven P, van Balkom AJ. Collaborative care for anxiety disorders in primary care: a systematic review and meta-analysis. BMC family practice. 2016 Jun 2:17():62. doi: 10.1186/s12875-016-0466-3. Epub 2016 Jun 2
[PubMed PMID: 27250527]
Level 1 (high-level) evidence